IP Library › Granted Patent US 11,491,001
Granted Patent B2
US 11,491,001 · App. 16/548,070 · Granted Nov 8, 2022

Implantable devices coated with extracellular matrix

Inventors: Ulrike W. Klueh (Birmingham, MI); Donald L. Kreutzer (Avon, CT)
Assignee: Cell and Molecular Tissue Engineering, LLC
A61F2/0063A61L31/10A61L31/16A61M5/158A61B5/14532A61B5/686A61B2562/18A61F2240/001A61F2250/0067A61L2300/414A61L2300/64A61M2005/1581A61M2205/0205
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,491,001
App. No.
16/548,070
Granted
Nov 8, 2022
Kind
B2
Abstract

Disclosed herein are medical products, including an implantable device coated with a crosslinked extracellular matrix comprising at least one of Type IV collagen and laminin, wherein the crosslinked extracellular matrix contains no more than 0.024 mg/ml total concentration of glucose, amino acids and salts having a molecular weight of 2000 daltons or less. Corresponding systems and method also are disclosed.

Claims (28)

1. An implantable device coated with a crosslinked extracellular matrix comprising at least one of Type IV collagen and laminin, wherein the crosslinked extracellular matrix contains no more than 0.024 mg/ml total concentration of glucose, amino acids and salts having a molecular weight of 2000 daltons or less.

2. The implantable device of claim 1 , wherein the crosslinked extracellular matrix is dehydrated after being in the form of a gel at room temperature.

3. The implantable device of claim 1 , wherein the crosslinked extracellular matrix is applied in multiple layers, and the extracellular matrix is dehydrated after application of each layer.

4. The implantable device of claim 1 , wherein the crosslinked extracellular matrix contains at least one of cells and factors, the factors being at least one member selected from the group consisting of angiogenic factors, drugs, antimicrobials, cytokines, growth factors and anti-inflammatory factors.

5. The implantable device of claim 1 , wherein the crosslinked extracellular matrix contains a factor that includes at least one of a vascular endothelial growth factor (VEGF), a hepatocyte growth factor and a fibroblast growth factor.

6. The implantable device of claim 1 , wherein the extracellular matrix is crosslinked with a dialdehyde.

7. The implantable device of claim 4 , wherein the cells and/or factors are bonded to the crosslinked extracellular matrix.

8. The implantable device of claim 1 , wherein the crosslinked extracellular matrix comprises cell culture derived extracellular matrix.

9. The implantable device of claim 1 , wherein the implantable device comprises at least one member selected from the group consisting of sensors, meshes, stents, and cannulas.

10. A kit comprising the implantable device of claim 1 enclosed in sterile packaging.

11. The implantable device of claim 1 , wherein the implantable device comprises a sensor.

12. The implantable device of claim 11 , wherein the crosslinked extracellular matrix contains at least one of cells and factors, the factors being at least one member selected from the group consisting of angiogenic factors, drugs, antimicrobials, cytokines, growth factors and anti-inflammatory factors.

13. The implantable device of claim 11 , wherein the crosslinked extracellular matrix contains a factor that includes at least one of a vascular endothelial growth factor, a hepatocyte growth factor and a fibroblast growth factor.

14. The implantable device of claim 11 , wherein the extracellular matrix is crosslinked with a dialdehyde.

15. The implantable device of claim 1 , wherein a synthetic matrix material is combined with the crosslinked extracellular matrix.

16. The implantable device of claim 1 , wherein the crosslinked extracellular matrix contains at least one member selected from the group consisting of anti-fibrotic agents, factors that promote angiogenesis and factors that promote lymphangiogenesis.

17. The implantable device of claim 1 , wherein the crosslinked extracellular matrix contains at least one of natural fibers and synthetic fibers.

18. The implantable device of claim 1 , wherein the crosslinked extracellular matrix contains at least one genetic element selected from the group consisting of DNAs, RNAs, viral vectors and plasmids.

19. The implantable device of claim 1 , wherein the crosslinked extracellular matrix contains at least one of siRNA, genetically altered RNA and chemically altered RNA.

20. The implantable device of claim 1 , wherein the crosslinked extracellular matrix contains cells.

21. The implantable device of claim 1 , wherein the crosslinked extracellular matrix contains at least one of VEGF-A, VEGF-B, VEGF-C and VEGF-D.

22. The implantable device of claim 1 , wherein the crosslinked extracellular matrix contains at least one of adenoviral vectors used in gene transfer and retroviral vectors used in gene transfer and plasmids used in gene transfer.

23. The implantable device of claim 1 , wherein the crosslinked extracellular matrix contains DNA used in plasmid gene transfer.

24. The implantable device of claim 1 , wherein the crosslinked extracellular matrix contains protein.

25. The implantable device of claim 1 , wherein the crosslinked extracellular matrix contains RNA.

26. The implantable device of claim 1 , wherein the crosslinked extracellular matrix contains a viral vector.

27. The implantable device of claim 1 , wherein the crosslinked extracellular matrix contains an antimicrobial agent.

28. The implantable device of claim 1 , wherein the crosslinked extracellular matrix is crosslinked with fibronectin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2019
From: KLUEH, ULRIKE W.; KREUTZER, DONALD L.
To: CELL AND MOLECULAR TISSUE ENGINEERING, LLC
Reel/Frame 050142/0041 →
Continuity (5)
Continuation 15255484 · Sep 2, 2016
Continuation In Part PCTUS2015049718 · Sep 11, 2015
Continuation In Part 14485313 · Sep 12, 2014
Continuation In Part 13828854 · Mar 14, 2013
Related Publication 20200069409A1 · Mar 5, 2020